- Home
- MCHX vs PROK Comparison
MCHX vs PROK Comparison
Compare MCHX & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCHX
- PROK
- Stock Information
- Founded
- MCHX 2003
- PROK 2015
- Country
- MCHX United States
- PROK United States
- Employees
- MCHX N/A
- PROK N/A
- Industry
- MCHX Business Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCHX Consumer Discretionary
- PROK Health Care
- Exchange
- MCHX Nasdaq
- PROK Nasdaq
- Market Cap
- MCHX 84.3M
- PROK 94.9M
- IPO Year
- MCHX 2004
- PROK N/A
- Fundamental
- Price
- MCHX $1.90
- PROK $0.79
- Analyst Decision
- MCHX
- PROK Buy
- Analyst Count
- MCHX 0
- PROK 4
- Target Price
- MCHX N/A
- PROK $5.00
- AVG Volume (30 Days)
- MCHX 43.2K
- PROK 511.4K
- Earning Date
- MCHX 05-13-2025
- PROK 05-12-2025
- Dividend Yield
- MCHX N/A
- PROK N/A
- EPS Growth
- MCHX N/A
- PROK N/A
- EPS
- MCHX N/A
- PROK N/A
- Revenue
- MCHX $47,951,000.00
- PROK $306,000.00
- Revenue This Year
- MCHX $6.83
- PROK $54.34
- Revenue Next Year
- MCHX N/A
- PROK N/A
- P/E Ratio
- MCHX N/A
- PROK N/A
- Revenue Growth
- MCHX N/A
- PROK N/A
- 52 Week Low
- MCHX $1.26
- PROK $0.46
- 52 Week High
- MCHX $2.40
- PROK $3.81
- Technical
- Relative Strength Index (RSI)
- MCHX 66.93
- PROK 50.86
- Support Level
- MCHX $1.54
- PROK $0.71
- Resistance Level
- MCHX $1.74
- PROK $0.82
- Average True Range (ATR)
- MCHX 0.13
- PROK 0.06
- MACD
- MCHX 0.03
- PROK 0.01
- Stochastic Oscillator
- MCHX 95.74
- PROK 48.17
About MCHX Marchex Inc. Class B
Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.